Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.
Department of Hepatobiliary and Pancreatic Surgery, Shulan (Hangzhou) Hospital, Hangzhou 310003, Zhejiang Province, China.
World J Gastroenterol. 2020 Jul 21;26(27):3851-3864. doi: 10.3748/wjg.v26.i27.3851.
Metabolic disease, including diabetes mellitus, hypertension, dyslipidemia, obesity, and hyperuricemia, is a common complication after liver transplantation and a risk factor for cardiovascular disease and death. The development of metabolic disease is closely related to the side effects of immunosuppressants. Therefore, optimization of the immunosuppressive regimen is very important for the prevention and treatment of metabolic disease. The Chinese Society of Organ Transplantation has developed an expert consensus on the management of metabolic diseases in Chinese liver transplant recipients based on recent studies. Emphasis is placed on the risk factors of metabolic diseases, the effect of immunosuppressants on metabolic disease, and the prevention and treatment of metabolic diseases.
代谢性疾病，包括糖尿病、高血压、血脂异常、肥胖和高尿酸血症，是肝移植后的常见并发症，也是心血管疾病和死亡的危险因素。代谢性疾病的发生与免疫抑制剂的副作用密切相关。因此，优化免疫抑制方案对于预防和治疗代谢性疾病非常重要。中国器官移植学会基于最近的研究，制定了中国肝移植受者代谢性疾病管理的专家共识。重点介绍了代谢性疾病的危险因素、免疫抑制剂对代谢性疾病的影响以及代谢性疾病的防治。
